I'm gonna do a topic presentation in dyslipidemia so give me info and intro, pathophysiology, risk factors , clinical presentation, lab investigation, classification and diagnostic criteria, treatment and management ( pharmacological and non pharmacological ). From recent guidelines for dyslipidemia AHA 2026 and ESC 2025 guidelines compare it
Reading File
Finding Sources
Searching the Web
AHA 2026 dyslipidemia guidelines recommendations LDL targets
Searching the Web
ESC 2025 dyslipidemia guidelines lipid management cardiovascular risk
Searching PubMed
dyslipidemia management guidelines lipid lowering
Reading File
Reading File
Reading Web Page
dyslipidemia guidelines LDL targets risk stratification treatment recommendations comparison
Finding Sources
Finding Sources
Reading Web Page
ESC 2025 dyslipidemia LDL targets risk categories treatment algorithm PCSK9 bempedoic
Reading File
Finding Sources
Reading File
Finding Sources
Loading Image
Loading Image
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Here is everything you need for your dyslipidemia presentation, organized and complete. Let me give you a quick orientation of what's covered:
What's in this guide:
- Introduction - epidemiology, global burden, why LDL matters
- Pathophysiology - complete lipoprotein metabolism cycle with diagrams (exogenous/endogenous pathways, atherogenesis mechanism)
- Risk Factors - non-modifiable, modifiable, and a full secondary causes table (hypothyroidism, CKD, HIV/ART, drugs, etc.)
- Clinical Presentation - signs (xanthomas, xanthelasma, corneal arcus, lipemia retinalis) + complications (ACS, pancreatitis, PAD)
- Lab Investigations - standard lipid panel with thresholds + advanced testing (Lp(a), ApoB, CAC, hsCRP)
- Classification - full Fredrickson Types I-V with the diagram from Lippincott's, plus modern primary/secondary classification
- Treatment - non-pharmacological (diet, exercise, lifestyle) + complete drug table (statins through evinacumab/volanesorsen)
- AHA 2026 vs ESC 2025 comparison - side-by-side across risk tools, LDL targets, treatment algorithms, novel agents, and where they agree vs differ
Key guideline highlights to emphasize in your presentation:
- AHA 2026: LDL targets are back after the 2018 guidelines abandoned them; PREVENT tool replaces PCE; universal Lp(a) for all adults; pediatric screening at age 9-11
- ESC 2025: Transitions from SCORE → SCORE2/SCORE2-OP; bempedoic acid gets Class I for statin-intolerant patients; adds evinacumab for HoFH and volanesorsen for familial chylomicronemia; stronger push to start LLT during ACS hospitalization
- Both agree: same LDL targets (<55, <70, <100 by risk tier), statins are first-line, stepwise add-on therapy
Make it short to for fast and detailed presentation to doc
Here is the condensed, high-yield version - every section tight and presentation-ready for a medical audience.
DYSLIPIDEMIA - High-Yield Presentation Summary
1. INTRO & OVERVIEW
- Abnormal plasma lipids: ↑ LDL-C, ↑ TG, ↓ HDL-C, or ↑ total cholesterol
- Affects 1 in 4 adults worldwide; major modifiable ASCVD risk factor
- Every 1 mmol/L ↓ LDL-C = ~22% ↓ major CV events (causal, linear, lifelong relationship)
- 2026 ACC/AHA guideline replaces 2018; ESC/EAS 2025 is a focused update of 2019
2. PATHOPHYSIOLOGY
Two pathways → both lead to LDL accumulation:
| Pathway | Key Steps |
|---|---|
| Exogenous | Dietary fat → intestine → chylomicrons → LPL hydrolysis → remnants → liver |
| Endogenous | Liver → VLDL → IDL → LDL → LDL receptor uptake by tissues |
| Reverse | Peripheral cholesterol → HDL → liver → bile excretion |
Atherogenesis sequence:
LDL enters endothelium → oxidized (ox-LDL) → macrophage uptake → foam cells → fatty streak → fibrous plaque → rupture → ACS
Key molecular drivers:
- ↓ LDL receptor activity (FH) → LDL accumulates
- Insulin resistance → ↑ VLDL, ↓ HDL, small dense LDL (most atherogenic)
- PCSK9 degrades LDL receptors → ↑ circulating LDL
- Lp(a) - pro-atherogenic + pro-thrombotic; genetically determined
3. RISK FACTORS
| Category | Examples |
|---|---|
| Non-modifiable | Age, male sex, family history / FH, ethnicity (South Asians) |
| Modifiable | High saturated/trans fat diet, obesity, sedentary lifestyle, smoking, excess alcohol |
| Secondary causes | Hypothyroidism (↑ LDL), T2DM (↑ TG, ↓ HDL), nephrotic syndrome (↑ LDL), CKD (↑ TG), cholestasis (↑ TC), HIV/ART - especially PIs (↑ TG, ↑ LDL), drugs: thiazides, beta-blockers, corticosteroids |
Always rule out secondary causes before labeling primary dyslipidemia
4. CLINICAL PRESENTATION
Mostly asymptomatic - found on screening
Physical signs (severe/familial cases):
| Sign | Condition |
|---|---|
| Tendinous / tuberous xanthomas | FH, Type IIA/III |
| Eruptive xanthomas | TG >500-1000 mg/dL (Types I, IV, V) |
| Xanthelasma | Hypercholesterolemia |
| Corneal arcus (<45 yrs) | FH |
| Lipemia retinalis | Severe hypertriglyceridemia (>2000 mg/dL) |
| Hepatosplenomegaly | Chylomicronemia |
Complications:
- Premature CAD / MI, Stroke, PAD
- Acute pancreatitis (TG >500-1000 mg/dL)
5. LAB INVESTIGATIONS
Standard Lipid Panel:
| Parameter | Optimal | High-Risk Target |
|---|---|---|
| LDL-C | <100 mg/dL | <55-70 mg/dL (see risk category) |
| HDL-C | ≥60 mg/dL (protective); <40 (men) / <50 (women) = low | |
| TG | <150 mg/dL | <150 |
| Non-HDL-C | <130 mg/dL | <85 (very high risk) |
| Total cholesterol | <200 mg/dL |
LDL calculation: Martin/Hopkins or Sampson/NIH equations preferred (2026 AHA Class I) - more accurate than Friedewald especially at low LDL or high TG
Advanced testing:
| Test | When / Why |
|---|---|
| Lp(a) | Once in all adults (AHA 2026 Class I); risk enhancer ≥125 nmol/L |
| ApoB | Better atherogenic particle count; guides intensification in TG, DM, metabolic syndrome |
| CAC score | Reclassifies risk when treatment decision uncertain |
| hsCRP | ≥2 mg/L → consider high-intensity statin |
| TSH, glucose/HbA1c, renal function, urine protein | Rule out secondary causes |
6. CLASSIFICATION
Fredrickson/WHO (Phenotypic)
| Type | Disorder | Elevated | LDL | TG | CHD Risk | Key Feature |
|---|---|---|---|---|---|---|
| I | Familial hyperchylomicronemia | Chylomicrons | N | ↑↑↑ | None | LPL/apo CII deficiency; pancreatitis; no drug works |
| IIA | Familial hypercholesterolemia | LDL | ↑↑ | N | ↑↑↑ | LDL receptor defect; xanthomas; early MI |
| IIB | Familial combined | LDL + VLDL | ↑ | ↑ | ↑↑ | Most common familial type; ↑ VLDL production |
| III | Dysbetalipoproteinemia | IDL | ↑ | ↑ | ↑↑ | ApoE2 mutation; palmar xanthomas |
| IV | Familial hypertriglyceridemia | VLDL | N/↑ | ↑↑ | ↑ | Common; obesity/DM |
| V | Mixed hypertriglyceridemia | VLDL + CM | N/↓ | ↑↑↑ | ↑ | Pancreatitis risk; obesity/DM |
Clinical Classification
- Primary: Genetic (FH, familial combined hyperlipidemia, Lp(a) excess)
- Secondary: Acquired (hypothyroidism, DM, CKD, drugs)
- Mixed: Both
FH Diagnostic Criteria
- LDL-C ≥190 mg/dL in adult + family history or tendon xanthomas
- Dutch Lipid Clinic Network Score or Simon Broome criteria (clinical + genetic)
7. TREATMENT & MANAGEMENT
Non-Pharmacological
| Intervention | Effect |
|---|---|
| Reduce saturated fat (<7% cal), eliminate trans fat | ↓ LDL 8-10% |
| Soluble fiber (oats, psyllium) | ↓ LDL 5-10% |
| Plant sterols/stanols (2 g/day) | ↓ LDL ~10% |
| Mediterranean / DASH diet | ↓ LDL + CV events |
| Exercise (150 min/week moderate aerobic) | ↑ HDL 5-10%, ↓ TG |
| Weight loss (5-10 kg) | ↓ LDL ~8%, ↓ TG ~20% |
| Smoking cessation | ↑ HDL, ↓ ox-LDL |
| Alcohol restriction | Essential for hypertriglyceridemia |
Pharmacological - Step-Up Approach
Step 1: STATIN (intensity based on risk)
↓ (goal not achieved)
Step 2: + EZETIMIBE
↓ (goal not achieved)
Step 3: + PCSK9 inhibitor (evolocumab/alirocumab)
OR inclisiran (siRNA, twice-yearly injection)
OR bempedoic acid (statin-intolerant)
Drug Table:
| Drug | Mechanism | LDL ↓ | Use |
|---|---|---|---|
| Statins (atorva, rosuva) | ↓ HMG-CoA reductase → ↑ LDL receptors | 30-65% | 1st line ALL |
| Ezetimibe | ↓ NPC1L1 intestinal absorption | +15-25% | Add-on |
| PCSK9 mAbs (evolocumab, alirocumab) | Prevent LDL receptor degradation | +50-65% | Very high risk |
| Inclisiran | siRNA ↓ PCSK9 production | +50% | Twice-yearly; alternative to PCSK9 mAb |
| Bempedoic acid | ↓ ACL (upstream of HMG-CoA) | +15-25% | Statin-intolerant |
| Bile acid sequestrants | ↑ LDL receptor via bile acid depletion | 15-30% | Limited (↑ TG) |
| Fibrates | PPAR-α → ↓ VLDL, ↑ LPL | TG ↓ 30-50% | TG ≥500 mg/dL |
| Icosapent ethyl (pure EPA) | ↓ VLDL secretion | TG ↓ 20-40% | High-risk + TG ≥150; REDUCE-IT trial |
| Evinacumab | Anti-ANGPTL3 → ↓ LDL independent of LDL-R | LDL ↓ ~50% | HoFH (NEW - ESC 2025) |
| Volanesorsen | ASO ↓ apo CIII → ↓ TG | TG ↓ 70-80% | Familial chylomicronemia (NEW - ESC 2025) |
| Lomitapide | ↓ MTP → ↓ VLDL/chylomicron assembly | LDL ↓ 40-50% | HoFH only |
8. GUIDELINE COMPARISON: ACC/AHA 2026 vs ESC/EAS 2025
At a Glance
| ACC/AHA 2026 | ESC/EAS 2025 | |
|---|---|---|
| Published | March 13, 2026 | August 2025 (ESC Congress, Madrid) |
| Type | Full new guideline (replaces 2018) | Focused update (of 2019) |
| Risk tool | PREVENT-ASCVD (10-year; ages 30-79) | SCORE2 (40-69) / SCORE2-OP (≥70) |
| Risk categories | Low <3%, Borderline 3-<5%, Intermediate 5-<10%, High ≥10% | Low, Moderate, High, Very High |
LDL-C Targets (BOTH AGREE)
| Risk Tier | Target |
|---|---|
| Very High (ASCVD + high-risk features) | <55 mg/dL + ≥50% reduction |
| High (ASCVD / high-risk primary) | <70 mg/dL + ≥50% reduction |
| Intermediate | <100 mg/dL |
| Low/Borderline | Lifestyle; consider statin |
Key Differences
| Feature | AHA 2026 | ESC 2025 |
|---|---|---|
| Lp(a) | Class I: measure in ALL adults (≥125 nmol/L = risk enhancer; ≥250 nmol/L = ≥2x risk) | Measure in FH / high-risk; >50 mg/dL = risk factor |
| Bempedoic acid | Option for statin-intolerant (Class IIa context) | Class I for statin-intolerant (stronger) |
| Evinacumab | Acknowledged for HoFH | NEW Class IIa for HoFH |
| Volanesorsen | Not specifically highlighted | NEW Class IIa for familial chylomicronemia |
| Pediatric screening | Universal at age 9-11 (new) | Selective |
| LDL formula | Martin/Hopkins preferred (Class I) | Friedewald acceptable |
| ApoB | Class IIa to guide intensification | Alternative to LDL-C |
| CAC scoring | Class I: CAC >0 → start LLT; CAC 0 → defer | Risk modifier |
| ACS | Early LLT initiation | Strong emphasis: start at index hospitalization |
| HIV patients | Treat per risk category | Statins recommended ≥40 yrs (new) |
| Dietary supplements | Not recommended | Explicitly not recommended |
Where They Fully Agree
- Same LDL-C absolute targets (<55 / <70 / <100 mg/dL)
- Statins = first-line universally
- Add ezetimibe → then PCSK9i/inclisiran stepwise
- Lifestyle change is foundational
- Icosapent ethyl for high-risk + elevated TG
- No supplements/vitamins for LDL reduction
Bottom line for your presentation:
AHA 2026 = broader scope (universal Lp(a), pediatric screening, lifetime risk, PREVENT tool, LDL targets reinstated)ESC 2025 = deeper refinement (SCORE2 tool, stronger push for bempedoic acid, novel agents for rare conditions, ACS timing)Both arrive at the same treatment targets - the difference is in how you stratify risk and which drugs get the strongest endorsement
This is a shared conversation. Sign in to Orris to start your own chat.